A new vaccine candidate, WRSs2, offers a glimmer of hope in the fight against diarrheal disease, a leading cause of death worldwide, particularly among children. Named after the Walter Reed Army Institute of Research, this vaccine has shown remarkable efficacy in a recent trial, providing 89% protection against shigellosis, one of the primary bacterial causes of diarrheal deaths.
The vaccine's development is a significant breakthrough, considering the challenges posed by the "poo taboo" in public health, which often leads to a lack of attention and understanding of diarrheal diseases. Dr. Robert Frenck, a professor of pediatrics and director of the Center for Vaccine Research, highlights the devastating impact of diarrheal illness on children globally, with Shigella being a common culprit in bacterial diarrhoea.
The trial, conducted at Cincinnati Children's Hospital Medical Center and the Emory Vaccine Center's Hope Clinic, involved 108 adults, with half receiving the vaccine and the other half receiving a placebo. The vaccine, a weakened version of the shigella bacteria, was administered in a liquid form, similar to a yogurt, with a dose taken twice a month apart. The results were impressive, with 81% of the placebo group contracting the illness, compared to only 11% in the vaccinated group.
Dr. Kawsar Talaat, an infectious disease physician and vaccine scientist, emphasizes the significance of the trial's setup, noting that the deliberate exposure to the bacteria in the placebo group highlights the vaccine's effectiveness. The vaccine's ability to prevent almost 90% of the illness is considered remarkable, especially given the small number of participants.
The impact of this vaccine is particularly crucial for children, who are at a higher risk of developing prolonged diarrhoea, hospitalization, malnutrition, and cognitive impairment due to Shigella. Dr. Jahangir Hossain, a researcher at the London School of Hygiene & Tropical Medicine, has witnessed the devastating effects of shigellosis in Bangladesh and West Africa, where poor sanitation and limited diagnostic resources exacerbate the problem.
The vaccine's development is timely, as increasing antibiotic resistance complicates the treatment of shigellosis. Dr. Hossain notes that antimicrobial resistance is a significant challenge, with some antibiotics becoming ineffective against certain strains of Shigella. The need for a vaccine becomes even more pressing as antibiotic resistance rises, potentially leading to higher mortality rates.
However, the vaccine is not without its challenges. While it is effective against a single species of Shigella, further research is required to develop a combination vaccine that can protect against multiple bacterial causes of diarrheal deaths, including ETEC, Campylobacter, and other pathogens. Dr. Hossain expresses caution about the practicality of combining multiple serotypes and pathogens, given the decades-long duration of vaccine trials.
Despite these considerations, the consensus among experts is that the next step is to ensure the vaccine's effectiveness in children, particularly those under 5 years old, who are the most vulnerable population. The vaccine's success in adults is a promising start, but larger trials in diverse populations are essential to assess its efficacy and safety in children.
In conclusion, the WRSs2 vaccine candidate represents a significant advancement in the fight against diarrheal disease, offering a potential solution to a global health crisis. With further research and development, this vaccine could save countless lives and reduce the burden of diarrheal illness, especially in regions with poor sanitation and limited access to healthcare.
